Skip to main content

Table 1 Case demographics of cases used in the study

From: Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS

Cases Disease group Age at onset Age at death Disease duration Gender Post-mortem delay (hours)
1 FTLD-FUS 41 43 2 F 55
2 FTLD-FUS 44 46 2 M 96
3 FTLD-FUS 63 59 6 F 2
4 FTLD-FUS 43 46 3 F 30
5 FTLD-FUS 69 72 3 F 90
6 FTLD-FUS 66 69 3 F 102
7 FTLD-FUS 49 55 6 F 3.5
8 FTLD-FUS 43 53 10 F 96
9 FTLD-FUS 55 58 3 F N/A
10 FTLD-FUS 40 51 11 M 12
11 FTLD-FUS 44 51 7 M 24
12 FTLD-FUS 47 53 6 M 5
13 FTLD-FUS 51 60 9 M 48
FTLD-FUS summary 50 (9.5) 55 (8.5) 5.5 (3) 5 M:8F 47 (40)
14 FTLD-TDP A 66 74 8 F 86
15 FTLD-TDP A 43 45 2 M 26
16 FTLD-TDP A 53 63 10 M 77
17 FTLD-TDP A 62 68 6 M 99
18 FTLD-TDP A 58 67 9 F 115
19 FTLD-TDP A 56 67 11 F 85.5
20 FTLD-TDP A 57 62 5 F 63
21 FTLD-TDP A 66 71 5 M 52
22 FTLD-TDP A 58 66 8 F 107
23 FTLD-TDP A 47 53 6 M 34
24 FTLD-TDP A 53 61 8 M 72.5
25 FTLD-TDP A 57 62 5 M 93
26 FTLD-TDP A 62 72 10 M 97.5
27 FTLD-TDP A 49 55 6 M 29
28 FTLD-TDP A 75 78 3 F 36
29 FTLD-TDP A 83 87 4 F 69
30 FTLD-TDP A 57 63 6 F 85
31 FTLD-TDP A 72 79 7 F 50
32 FTLD-TDP A 62 68 6 F 100
FTLD-TDP A summary 59 (10) 66 (10) 6.6 (2.4) 9 M:10F 71 (28)
33 FTLD-TDP B 67 69 2 M 70
34 FTLD-TDP B 63 67 4 F 45.5
35 FTLD-TDP B 63 83 20 F 45
FTLD-TDP B summary 64.3 (2.3) 73 (8.7) 8.6 (9.8) 1 M:2F 53.5 (14)
36 FTLD-TDP C 58 73 15 F 38
37 FTLD-TDP C 59 73 14 F 84
38 FTLD-TDP C 64 78 14 M 27
39 FTLD-TDP C 64 74 10 M 19
40 FTLD-TDP C 50 65 15 M 52
41 FTLD-TDP C 61 66 5 M 71
42 FTLD-TDP C 44 67 23 M 76
FTLD-TDP C summary 57.1 (7.5) 70.8 (4.9) 13.7 (5.5) 5 M:2F 52 (25)
43 Control 80 N/A N/A M 16
44 Control 79 N/A N/A F 89
45 Control 80 N/A N/A F 49
46 Control 93 N/A N/A F 30
47 Control 73 N/A N/A F 24
48 Control 83 N/A N/A F 20
Control summary 81.3 (6.6) N/A N/A 1 M:5F 14 (3.5)
\